132 related articles for article (PubMed ID: 38419514)
21. Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population.
Liu C; Li N; Sheng D; Shao Y; Qiu L; Shen C; Liu Z
Lipids Health Dis; 2024 Apr; 23(1):104. PubMed ID: 38616253
[TBL] [Abstract][Full Text] [Related]
22. Childhood maltreatment and risk of metabolic dysfunction-associated steatotic liver disease - Evidence of sex-specific associations in the general population.
Siewert-Markus U; Ittermann T; Klinger-König J; Grabe HJ; Stracke S; Völzke H; Targher G; Dörr M; Markus MRP; Töpfer P
J Psychosom Res; 2024 Aug; 183():111829. PubMed ID: 38896985
[TBL] [Abstract][Full Text] [Related]
23. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
[TBL] [Abstract][Full Text] [Related]
25. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
Wakabayashi SI; Tamaki N; Kimura T; Umemura T; Kurosaki M; Izumi N
J Gastroenterol; 2024 Jun; 59(6):494-503. PubMed ID: 38570344
[TBL] [Abstract][Full Text] [Related]
26. Bioelectrical impedance parameters add incremental value to waist-to-hip ratio for prediction of metabolic dysfunction associated steatotic liver disease in youth with overweight and obesity.
Song K; Seol EG; Yang H; Jeon S; Shin HJ; Chae HW; Kim EK; Kwon YJ; Lee JW
Front Endocrinol (Lausanne); 2024; 15():1385002. PubMed ID: 38883602
[TBL] [Abstract][Full Text] [Related]
27. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
[TBL] [Abstract][Full Text] [Related]
28. Association of metabolic syndrome with erosive esophagitis and Barrett's esophagus in a Chinese population.
Lee SW; Lien HC; Chang CS; Lee TY; Peng YC; Yeh HZ
J Chin Med Assoc; 2017 Jan; 80(1):15-18. PubMed ID: 27756532
[TBL] [Abstract][Full Text] [Related]
29. Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study.
Jung YM; Lee SM; Wi W; Oh MJ; Park JS; Cho GJ; Kim W
JHEP Rep; 2024 Apr; 6(4):101033. PubMed ID: 38524668
[TBL] [Abstract][Full Text] [Related]
30. Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease.
Min Y; Wei X; Wei Z; Song G; Zhao X; Lei Y
Cardiovasc Diabetol; 2024 Jun; 23(1):188. PubMed ID: 38824550
[TBL] [Abstract][Full Text] [Related]
31. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
[TBL] [Abstract][Full Text] [Related]
32. Subtypes of metabolic syndrome and of other risk factors in Japanese women with erosive esophagitis.
Sogabe M; Okahisa T; Yamanoi A; Takayama T
Medicine (Baltimore); 2014 Dec; 93(28):e276. PubMed ID: 25526458
[TBL] [Abstract][Full Text] [Related]
33. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
[TBL] [Abstract][Full Text] [Related]
34. Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis.
Kobayashi N; Tada T; Nishimura T; Matono T; Yuri Y; Takashima T; Aizawa N; Ikeda N; Fukunishi S; Hashimoto M; Ohyanagi M; Enomoto H; Iijima H
Hepatol Res; 2024 May; 54(5):429-438. PubMed ID: 38015179
[TBL] [Abstract][Full Text] [Related]
35. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
[TBL] [Abstract][Full Text] [Related]
36. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.
Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994
[TBL] [Abstract][Full Text] [Related]
37. Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study.
Sogabe M; Okahisa T; Kagawa M; Sei M; Kagemoto K; Tanaka H; Kida Y; Nakamura F; Tomonari T; Okamoto K; Miyamoto H; Sato Y; Nakasono M; Takayama T
J Gastroenterol Hepatol; 2024 Apr; 39(4):754-761. PubMed ID: 38212880
[TBL] [Abstract][Full Text] [Related]
38. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
39. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
[TBL] [Abstract][Full Text] [Related]
40. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study.
Simon TG; Ebrahimi F; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
Cardiovasc Diabetol; 2023 Dec; 22(1):343. PubMed ID: 38093277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
